340B program remains second largest federal drug program, yet little solid evidence of benefits to patient

Over the three decades since Congress created the 340B drug pricing program, we ’ve seen massive growth in its size. As a program meant to serve vulnerable patients, this sounds great, right? The problem is we’ve seen little to no evidence patients are benefiting from this growth or even the program itself. Instead, large hospital systems, for-profit pharmacies and other mi ddlemen have co-opted 340B – a program meant to help patients – and turned it into a profit center. At the same time, the program creates incentives thatdrive up costs for all of us.
Source: The Catalyst - Category: Pharmaceuticals Tags: 340B Source Type: news